JP2021510710A5 - - Google Patents
Info
- Publication number
- JP2021510710A5 JP2021510710A5 JP2020539000A JP2020539000A JP2021510710A5 JP 2021510710 A5 JP2021510710 A5 JP 2021510710A5 JP 2020539000 A JP2020539000 A JP 2020539000A JP 2020539000 A JP2020539000 A JP 2020539000A JP 2021510710 A5 JP2021510710 A5 JP 2021510710A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- nos
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018072607 | 2018-01-15 | ||
| CNPCT/CN2018/072607 | 2018-01-15 | ||
| PCT/CN2019/071711 WO2019137548A1 (en) | 2018-01-15 | 2019-01-15 | Antibodies and variants thereof against tigit |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510710A JP2021510710A (ja) | 2021-04-30 |
| JP2021510710A5 true JP2021510710A5 (https=) | 2022-02-07 |
| JP7316284B2 JP7316284B2 (ja) | 2023-07-27 |
Family
ID=67219401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539000A Active JP7316284B2 (ja) | 2018-01-15 | 2019-01-15 | Ｔｉｇｉｔに対する抗体及びその多様体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11708410B2 (https=) |
| EP (1) | EP3740508A4 (https=) |
| JP (1) | JP7316284B2 (https=) |
| KR (1) | KR20200109313A (https=) |
| CN (1) | CN111601826B (https=) |
| AU (1) | AU2019207296A1 (https=) |
| CA (1) | CA3088332A1 (https=) |
| IL (1) | IL275737A (https=) |
| SG (1) | SG11202005595YA (https=) |
| TW (1) | TW201932489A (https=) |
| WO (1) | WO2019137548A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| WO2022105872A1 (zh) * | 2020-11-23 | 2022-05-27 | 广东菲鹏制药股份有限公司 | 抗tigit抗体或其抗原结合片段 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| CN114539418A (zh) * | 2020-11-26 | 2022-05-27 | 上海华奥泰生物药业股份有限公司 | 双特异性抗体及其用途 |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CN115466327B (zh) * | 2021-06-10 | 2025-07-08 | 北京天广实生物技术股份有限公司 | 结合tigit的抗体及其用途 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2023020625A1 (zh) * | 2021-08-20 | 2023-02-23 | 中山康方生物医药有限公司 | 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023138639A1 (zh) * | 2022-01-24 | 2023-07-27 | 原启生物科技(上海)有限责任公司 | 靶向tigit的抗原结合蛋白及其用途 |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| CN120202220A (zh) * | 2022-08-26 | 2025-06-24 | 南京传奇生物科技有限公司 | 靶向tigit的抗体及其用途 |
| CN116444653B (zh) * | 2023-03-09 | 2024-03-15 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2025002151A1 (zh) * | 2023-06-27 | 2025-01-02 | 正大天晴药业集团股份有限公司 | 抗tigit抗体及其应用 |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| CN118290586B (zh) * | 2024-04-02 | 2025-11-04 | 郑州伊美诺生物技术有限公司 | 一种分泌kod dna聚合酶单克隆抗体的杂交瘤细胞、单克隆抗体及其应用 |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| CN120647762B (zh) * | 2025-06-16 | 2026-01-23 | 首都医科大学附属北京友谊医院 | 一种抗β1-AR-ECII抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073644B (zh) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| EP3169363A4 (en) * | 2014-07-16 | 2018-02-21 | F. Hoffmann-La Roche AG | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| MD4733C1 (ro) * | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anticorpi anti-TIGIT |
| CA3138083A1 (en) | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| PE20181046A1 (es) * | 2015-09-25 | 2018-07-03 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso |
| PT3356413T (pt) * | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
| WO2018128939A1 (en) * | 2017-01-05 | 2018-07-12 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
-
2019
- 2019-01-15 AU AU2019207296A patent/AU2019207296A1/en not_active Abandoned
- 2019-01-15 KR KR1020207020419A patent/KR20200109313A/ko not_active Withdrawn
- 2019-01-15 CA CA3088332A patent/CA3088332A1/en active Pending
- 2019-01-15 SG SG11202005595YA patent/SG11202005595YA/en unknown
- 2019-01-15 WO PCT/CN2019/071711 patent/WO2019137548A1/en not_active Ceased
- 2019-01-15 JP JP2020539000A patent/JP7316284B2/ja active Active
- 2019-01-15 EP EP19738954.7A patent/EP3740508A4/en not_active Withdrawn
- 2019-01-15 TW TW108101551A patent/TW201932489A/zh unknown
- 2019-01-15 CN CN201980008439.XA patent/CN111601826B/zh active Active
- 2019-01-15 US US15/733,364 patent/US11708410B2/en active Active
-
2020
- 2020-06-29 IL IL275737A patent/IL275737A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510710A5 (https=) | ||
| JP7813721B2 (ja) | Ｎｅｃｔｉｎ－４に対する抗体及びその用途 | |
| JP7562528B2 (ja) | 抗体及びその用途 | |
| JP7150880B2 (ja) | 抗－ｂ７－ｈ３抗体およびその用途 | |
| CN115052895B (zh) | 抗SIRPα抗体及其用途 | |
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| JP2021524242A (ja) | 抗−ｒｏｒ１抗体およびその用途 | |
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2015519375A5 (https=) | ||
| WO2018053709A1 (en) | The novel monoclonal antibodies to programmed death 1 (pd-1) | |
| JP2019527553A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| IL261666B2 (en) | Binding proteins and methods of use thereof | |
| CN111635458A (zh) | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 | |
| JP7821159B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| JP2024001073A5 (https=) | ||
| CN113993901A (zh) | 四价双特异性抗体、其制备方法和用途 | |
| JP2024515560A5 (https=) | ||
| JP2025541367A (ja) | 多価および多重特異性サイトカインアンタゴニスト | |
| CA3208368A1 (en) | Vegfa-binding molecules | |
| WO2021084104A1 (en) | Tetravalent antibody molecules | |
| JP7821161B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| CN120035609A (zh) | Pd-1激动剂抗体 | |
| EP3841122A1 (en) | Anti-sirpg compounds | |
| US20250011431A1 (en) | Anti-canine pd-l1 antibodies |